BR112016024332A2 - métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização - Google Patents
métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilizaçãoInfo
- Publication number
- BR112016024332A2 BR112016024332A2 BR112016024332A BR112016024332A BR112016024332A2 BR 112016024332 A2 BR112016024332 A2 BR 112016024332A2 BR 112016024332 A BR112016024332 A BR 112016024332A BR 112016024332 A BR112016024332 A BR 112016024332A BR 112016024332 A2 BR112016024332 A2 BR 112016024332A2
- Authority
- BR
- Brazil
- Prior art keywords
- gdc
- therapeutic efficacy
- treatment
- methods
- biomarker
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Abstract
a presente invenção se refere aos métodos e às composições que são fornecidas para o tratamento de câncer de mama em pacientes com um inibidor de pi3k, gdc-0941 em combinação com um agente de terapia endócrina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462001205P | 2014-05-21 | 2014-05-21 | |
PCT/EP2015/061051 WO2015177184A1 (en) | 2014-05-21 | 2015-05-20 | Methods of treating pr-positive, luminal a breast cancer with pi3k inhibitor, pictilisib |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016024332A2 true BR112016024332A2 (pt) | 2017-08-15 |
Family
ID=53189067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016024332A BR112016024332A2 (pt) | 2014-05-21 | 2015-05-20 | métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização |
Country Status (11)
Country | Link |
---|---|
US (1) | US10004748B2 (pt) |
EP (1) | EP3145509A1 (pt) |
JP (1) | JP2017515873A (pt) |
KR (1) | KR20170005419A (pt) |
CN (1) | CN106456776A (pt) |
BR (1) | BR112016024332A2 (pt) |
CA (1) | CA2945068A1 (pt) |
MA (1) | MA40271A (pt) |
MX (1) | MX2016015161A (pt) |
RU (1) | RU2016148441A (pt) |
WO (1) | WO2015177184A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7144934B2 (ja) | 2015-03-25 | 2022-09-30 | ザ ジェネラル ホスピタル コーポレイション | 血液試料中の循環腫瘍細胞のデジタル分析 |
WO2017117386A1 (en) * | 2015-12-30 | 2017-07-06 | Icahn School Of Medicine At Mount Sinai | Methods of treating cancer using network brakes |
US20170363632A1 (en) * | 2016-06-15 | 2017-12-21 | University Of Maryland, Baltimore | Biomarker Kit for Metastatic Breast Cancer Prognosis and Uses Thereof |
US20190192501A1 (en) * | 2016-08-23 | 2019-06-27 | Icahn School Of Medicine At Mount Sinai | Methods for treating pten-mutant tumors |
US11371101B2 (en) * | 2016-10-27 | 2022-06-28 | The General Hospital Corporation | Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers |
CN117281814A (zh) * | 2018-07-23 | 2023-12-26 | 豪夫迈·罗氏有限公司 | 用pi3k抑制剂gdc-0077治疗癌症的方法 |
WO2023035614A1 (zh) * | 2021-09-10 | 2023-03-16 | 上海海和药物研究开发股份有限公司 | 包含PI3Kα抑制剂的药物组合 |
TW202315635A (zh) * | 2021-09-30 | 2023-04-16 | 大陸商廣州嘉越醫藥科技有限公司 | 一種藥物組合及其應用 |
WO2023196899A2 (en) * | 2022-04-08 | 2023-10-12 | Global Cancer Technology | Methods and products to screen and treat glioblastoma multiforme and other cancers, including breast cancers, using a combination of pi3kinase inhibitors with checkpoint inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
US7781433B2 (en) | 2006-04-26 | 2010-08-24 | Piramed Limited | Pharmaceutical compounds |
CN101939006B (zh) | 2007-09-12 | 2015-09-16 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法 |
KR101781654B1 (ko) | 2009-03-12 | 2017-09-25 | 제넨테크, 인크. | 조혈 악성종양의 치료를 위한 포스포이노시티드 3-키나제 억제제 화합물 및 화학요법제의 조합물 |
GB0912999D0 (en) * | 2009-07-27 | 2009-09-02 | Astrazeneca Ab | Method-803 |
US20140235630A1 (en) * | 2011-09-30 | 2014-08-21 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for the treatment of proliferative diseases |
RU2603462C2 (ru) | 2011-10-13 | 2016-11-27 | Дженентек, Инк. | Лечение фармакологически индуцированной гипохлоргидрии |
AU2012340186A1 (en) | 2011-11-18 | 2014-06-19 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
CN104379163A (zh) * | 2012-06-08 | 2015-02-25 | 霍夫曼-拉罗奇有限公司 | 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合 |
-
2015
- 2015-05-20 KR KR1020167032063A patent/KR20170005419A/ko unknown
- 2015-05-20 EP EP15723238.0A patent/EP3145509A1/en not_active Withdrawn
- 2015-05-20 MA MA040271A patent/MA40271A/fr unknown
- 2015-05-20 MX MX2016015161A patent/MX2016015161A/es unknown
- 2015-05-20 RU RU2016148441A patent/RU2016148441A/ru not_active Application Discontinuation
- 2015-05-20 CN CN201580026974.XA patent/CN106456776A/zh active Pending
- 2015-05-20 CA CA2945068A patent/CA2945068A1/en not_active Abandoned
- 2015-05-20 JP JP2016568534A patent/JP2017515873A/ja active Pending
- 2015-05-20 US US14/717,069 patent/US10004748B2/en not_active Expired - Fee Related
- 2015-05-20 WO PCT/EP2015/061051 patent/WO2015177184A1/en active Application Filing
- 2015-05-20 BR BR112016024332A patent/BR112016024332A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX2016015161A (es) | 2017-03-27 |
CA2945068A1 (en) | 2015-11-26 |
JP2017515873A (ja) | 2017-06-15 |
CN106456776A (zh) | 2017-02-22 |
US20150335650A1 (en) | 2015-11-26 |
EP3145509A1 (en) | 2017-03-29 |
MA40271A (fr) | 2017-03-29 |
US10004748B2 (en) | 2018-06-26 |
RU2016148441A3 (pt) | 2018-11-12 |
WO2015177184A1 (en) | 2015-11-26 |
RU2016148441A (ru) | 2018-06-22 |
KR20170005419A (ko) | 2017-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016024332A2 (pt) | métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização | |
CY1122247T1 (el) | Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3 | |
PH12017502391A1 (en) | Compositions and methods for inhibiting arginase activity | |
AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
CL2015002807A1 (es) | Terapia de combinación | |
NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
CR20160289A (es) | Compuestos de inhibidor de autotaxina | |
PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
CO7151491A2 (es) | Método para la identificación del origen de un cancer de origen primario desconocido | |
EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
BR112017015576A2 (pt) | método para o tratamento de câncer, artigo, método para monitorizar, método para a otimização da eficácia terapêutica, método para a identificação de um biomarcador, utilização, combinação terapêutica, combinação para a utilização e produto | |
IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
CY1121749T1 (el) | Προφαρμακα ανταγωνιστων nmda | |
BR112017025553A2 (pt) | composição de vacina, e kit | |
CO2018011200A2 (es) | Marcador para predecir la respuesta al tratamiento del agente anticancerígeno en pacientes con cáncer | |
UY35033A (es) | Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa | |
CL2016001361A1 (es) | Regimen de dosificación para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa | |
CR20140480A (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2568 DE 2020-03-24 |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |